Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,552 | 401 | 1,087 |
| Samples | 1,255 | 324 | 915 |
| Peptides | 1,086 | 209 | 865 |
Function
CELSR2 · Cadherin EGF LAG seven-pass G-type receptor 2
The protein encoded by this gene is a member of the flamingo subfamily, part of the cadherin superfamily. The flamingo subfamily consists of nonclassic-type cadherins; a subpopulation that does not interact with catenins. The flamingo cadherins are located at the plasma membrane and have nine cadherin domains, seven epidermal growth factor-like repeats and two laminin A G-type repeats in their ectodomain. They also have seven transmembrane domains, a characteristic unique to this subfamily. It is postulated that these proteins are receptors involved in contact-mediated communication, with cadherin domains acting as homophilic binding regions and the EGF-like domains involved in cell adhesion and receptor-ligand interactions. The specific function of this particular member has not been determined. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000271332 | Q9HCU4 | 1,552 | 1,086 |
Gene Properties
Recurrent Mutations
All 1086 amino-acid changes on canonical ENST00000271332 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CELSR2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CELSR2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 12/40 30% | 0/0 0% |
| Chronic Myelogenous Leukemia | 6/25 24% | 0/0 0% |
| Endometrial Carcinoma | 19/42 45% | 55/612 9% |
| Glioblastoma | 11/98 11% | 0/0 0% |
| Acute Myeloid Leukemia | 8/90 9% | 0/0 0% |
| Oral Cavity Carcinoma | 4/54 7% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 42/304 14% | 48/1390 3% |
| Colorectal Carcinoma | 33/143 23% | 146/3239 5% |
| Gastric Carcinoma | 10/74 14% | 82/1809 5% |
| Melanoma | 20/210 10% | 82/1899 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Other Solid Cancers | 4/94 4% | 52/1515 3% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 25/810 3% |
| Cervical Carcinoma | 2/35 6% | 13/422 3% |
| Bladder Carcinoma | 9/58 16% | 24/956 3% |
| Germ Cell Tumour | 2/25 8% | 4/169 2% |
| Hodgkins Lymphoma | 2/16 12% | 2/122 2% |
| Plasma Cell Myeloma | 6/44 14% | 4/305 1% |
| Neuroendocrine Tumour | 13/154 8% | 8/577 1% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 2/71 3% |
| Head and Neck Carcinoma | 10/85 12% | 31/1574 2% |
| Ovarian Carcinoma | 13/109 12% | 14/998 1% |
| Biliary Tract Carcinoma | 3/54 6% | 20/950 2% |
| Esophageal Carcinoma | 0/23 0% | 18/769 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Other Sarcomas | 6/69 9% | 11/699 2% |
| Mesothelioma | 4/62 6% | 1/165 1% |
| Non-Cancerous | 6/104 6% | 13/830 2% |
| Prostate Carcinoma | 2/13 15% | 31/2105 1% |
| Ewings Sarcoma | 3/63 5% | 2/262 1% |
Mutation Distribution
Where CELSR2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CELSR2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,552 mutations in CELSR2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|